VE 2843
Alternative Names: VE-2843Latest Information Update: 25 Jan 2023
At a glance
- Originator Verseon
- Class Antineoplastics; Small molecules
- Mechanism of Action Matriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer metastases
Most Recent Events
- 12 Jan 2023 Early research in Cancer metastases in USA (Unspecified) before January 2023 (Verseon pipeline, January 2023)